抗体药物偶联物 (ADC) 市场 - 按癌症类型、有效载荷、标靶、产品、用户和国家划分的市场预测（含高阶主管和顾问指南）：2026-2030

报告概述：

透过我们最新的报告了解该市场。我们分析了 100 家寻求发展机会的公司，并阐述了它们的计划。详细的市场分析仅用几页篇幅就展现了完整的市场概况。

从各个角度分析市场：癌症类型、酬载、标靶、产品、使用者和国家。了解市场机会。

该市场已是一个数十亿美元的全球市场，并蓄势待发，即将迎来爆发式增长。它对医疗保健行业的影响巨大。本报告预测了未来五年的市场规模。

识别机会和挑战，了解成长预测和最终市场规模潜力。

所有报表资料可依需求提供 Excel 格式。

利用最新数据和全面分析，做出自信的决策。

目录

第一章：市场指南

第二章：引言与市场定义

• 什么是抗体药物偶联物？
• 免疫疗法－未来的疗法
• 市场定义
• 研究方法
• 美国医疗保健市场与药品支出展望

第三章：抗体药物偶联物

• 免疫系统
  • 先天免疫系统
  • 适应性免疫系统
  • 肿瘤免疫学 - 免疫监视系统
• 抗体药物偶联物 (ADC) 技术

第四章：产业概览

• 市场参与者 - 角色与影响
  • 药品製造商 - 大型製药公司/製药公司
  • 药品製造商 - 仿製药
  • 合约研发生产机构 (CRDO)
  • 体外诊断产业
  • 药品行销公司
  • 生技公司
  • 监理机构

第五章：市场趋势

• 成长驱动因素
  • 潜在结果
  • 快速通道
  • 资金
  • 科技环境
  • 标靶解决方案
• 成长限制因素
  • 治疗成本
  • 临床试验的作用
  • 合併用药
  • 方案
• 治疗技术开发
  • 合併用药－问题与复杂性
  • 药物偏好
  • 免疫工程挑战
  • 成本的作用
  • 颠覆性动态
• 2024年全球抗体药物偶联物 (ADC) 销售额

第六章 近期ADC最新进展

• 最新进展 - 本部分的重要性和用途
• 默克获得7亿美元用于ADC疗法的开发
• Enhertu超越罗氏的Kadsila
• 信达生物与武田签署114亿美元的癌症治疗协议
• Tubuli融资3.58亿美元用于开发标靶癌症疗法
• 罗氏签署8000万美元的肺癌ADC协议
• Trodelvy和Keytruda联合疗法在3期临床试验中取得成功
• 葛兰素史克获得前列腺癌ADC的权利
• 三星Bioepis和Phrontline合作开发ADC
• Phrontline Biopharma融资6000万美元用于双特异性和双有效载荷ADC
• Kelun的ADC-Keytruda突破3期临床试验组合
• 达托泊单抗（Datopotamab Deruxtecan）生物製剂许可申请核准
• FDA核准第一三共和阿斯特捷利康的实体肿瘤治疗药物
• 阿斯特捷利康将投资15亿美元兴建ADC工厂
• 三星生物製剂拓展ADC生产与服务业务
• 益普生和Foreseen Biotechnology宣布ADC许可协议
• PDC与ADC：开拓新领域
• MilliporeSigma推出用于ADC生产的一次性反应器
• 小野洋子研发出新型ADC候选药物
• 吉利德和Tubulis开发用于实体肿瘤的ADC候选药物

第七章：主要ADC公司概览

• ADC疗法
• 艾伯维
• 阿布泽纳
• Adcendo
• Adcentrx 疗法
• Adcytherix
• Alentis 疗法
• 康宁杰瑞肿瘤学
• Alteogen
• Ambrx
• 安进
• Antengene
• 安斯泰来製药
• Axcynsis 疗法
• Axplora
• 百济神州
• BeOne 药品
• 生物阿特拉
• 百奥泰解决方案
• 比奥修斯
• BiVictriX 疗法
• 生物科技
• 自行车治疗
• 博尔特生物疗法
• 明峰疗法
• 百时美施贵宝(BMS)
• Byondis
• Callio Therapeutics
• Catalent Biologics
• CSPC Pharmaceutical Group
• CytomX Therapeutics
• Daiichi Sankyo
• Debiopharm
• Duality Biologics
• Eisai
• Eli Lilly
• Exelixis
• Fosun Pharma
• Genentech (Roche)
• Genmab
• GenScript Biotech
• Gilead Sciences
• GlaxoSmithKline (GSK)
• Hansoh Pharma
• Hengrui Pharma
• Heidelberg Pharma
• Iksuda Therapeutics
• ImmunoGen
• Innate Pharma
• Innovent Biologics
• iProgen生物技术
• 杨森生物技术（强生公司）
• 科伦生物技术
• KLUS製药
• 乐高化学生物科技（乐高化学生物）
• 乐普生物製药
• 龙沙製药/Synaffix
• MacroGenics
• MBrace Therapeutics
• MediLink Therapeutics
• 默克公司（默沙东）
• 默克集团（EMD Serono）
• Mersana Therapeutics
• Molecular Templates
• NBE Therapeutics（勃林格殷格翰子公司）
• 诺华
• OBI Pharma
• OmniAb
• Oncomatryx
• OnCusp Therapeutics
• Orum治疗药物
• Oqory
• Oxford BioTherapeutics
• Pacylex Pharmaceuticals
• 辉瑞
• Phrontline Biopharma
• ProfoundBio
• Promega
• Pyxis Oncology
• Radiance Biopharma
• Rakuten Aspyrian (Aspyrian Therapeutics)
• RemeGen
• 罗氏
• 荣昌製药 (RCBio)
• 赛诺菲
• Seagen
• Solve Therapeutics (Solve Tx)
• Sorrento Therapeutics
• Starpharma
• Sutro Biopharma
• Synaffix (Lonza旗下公司)
• SystImmune
• 武田製药
• Tesaro/葛兰素史克肿瘤学
• Tubulis
• UCB
• VelosBio
• 药明康德
• Xencor
• 再鼎医药

第八章：全球抗体偶联药物（ADC）市场

• 全球市场概览（依国家/地区划分）
• 全球市场概览（依癌症类型划分）
• 全球市场概览（依有效载荷划分）
• 全球市场概览（以标靶划分）
• 全球市场概览（依产品划分）
• 全球市场概览（依使用者划分）

第九章：全球ADC市场（依癌症类型划分）

• 乳癌
• 血液和淋巴系统癌症
• 肺癌
• 其他

第十章：ADC市场有效负载

• 阿里他汀类药物
• 美登木素生物碱
• 拓朴异构酶
• 其他

第 11 章 ADC 治疗市场 - 按目标

• HER2
• CD30
• TROP2
• CD79b
• Nectin-4
• 其他

第 12 章 ADC 治疗市场 - 按产品

• 恩赫图
• 卡德西拉
• 帕德切夫
• Adcetris
• 特罗德夫
• Polyvy
• 其他

第 13 章 ADC 治疗市场 - 作者使用者

• 临床
• 试用
• 研究
• 其他

第 14 章：附录

Report Overview:

Get a handle on this market with our latest report. We analyze 100 Companies who are rushing after the opportunity and explain their plans. A detailed Situation Analysis sums up the big picture in a few pages.

We look at the market from every angle: Cancer, Payload, Target, Product, User and Country. Understand this market opportunity.

Already worth billions the global market is poised for dramatic growth. The impact on the health care industry is enormous. The report forecasts the market size out for five years.

Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

All report data is available in Excel format on request.

Make decisions with confidence using the latest data and comprehensive analysis.

Table of Contents

1 Market Guides

• 1.1 Situation Analysis
• 1.2 Guide for Executives and Marketing Staff
• 1.3 Guide for Investment Analysts and Management Consultants

2 Introduction and Market Definition

• 2.1 What are Antibody Drug Conjugates?
• 2.2 Immunotherapy - the looming cures
• 2.3 Market Definition
  • 2.3.1 Market Size
  • 2.3.2 Currency
  • 2.3.3 Years
• 2.4 Methodology
  • 2.4.1 Methodology
  • 2.4.2 Sources
  • 2.4.3 Authors
• 2.5 U.S. Medical Market and Pharmaceutical Spending - Perspective
  • 2.5.1 Global Expenditures for Medicines

3 Antibody Drug Conjugates

• 3.1 The Immune System
  • 3.1.1 Innate immune system
    • 3.1.1.1 Surface barriers
    • 3.1.1.2 Inflammation
    • 3.1.1.3 Complement system
    • 3.1.1.4 Cellular barriers
    • 3.1.1.5 Natural killer cells
  • 3.1.2 Adaptive immune system
    • 3.1.2.1 Lymphocytes
    • 3.1.2.2 Killer T cells
    • 3.1.2.3 Helper T cells
    • 3.1.2.4 Gamma delta T cells
    • 3.1.2.5 B lymphocytes and antibodies
  • 3.1.3 Tumor immunology - the immune surveillance system
• 3.2 ADC Technology
  • 3.2.1.1 Outlook for Antibody Drug Conjugates
  • 3.2.1.2 Selected Companies with Antibody Drug Conjugates in their Pipeline

4 Industry Overview

• 4.1 Market Players - Roles & Impacts
  • 4.1.1 Drug manufacturers - Larger/pharmaceutical
  • 4.1.2 Drug manufacturers - Generic
  • 4.1.3 Contract Research and Manufacturing
  • 4.1.4 In Vitro Diagnostics Industry
  • 4.1.5 Drug Marketing Companies
  • 4.1.6 Biotechnology Companies
  • 4.1.7 Regulatory Bodies

5 Market Trends

• 5.1 Factors Driving Growth
  • 5.1.1 Outcome potential
  • 5.1.2 Fast tracking
  • 5.1.3 Funding
  • 5.1.4 Technology Environment
  • 5.1.5 Target Solutions
• 5.2 Factors Limiting Growth
  • 5.2.1 Cost of Treatment
  • 5.2.2 Clinical Trials Role
  • 5.2.3 Combinations
  • 5.2.4 Protocols
• 5.3 Therapeutic Technology Development
  • 5.3.1 Combinations - Issues and Complexity
  • 5.3.2 Preference for a drug
  • 5.3.3 Problems of Immunity Engineering
  • 5.3.4 The Role of Cost
  • 5.3.5 The Disruption Dynamic
• 5.4 Global Sales of Antibody-drug Conjugates (ADCs) in 2024
  • 5.4.1 Enhertu Sales in 2024/2023
  • 5.4.2 Kadcyla Sales in 2024/2023
  • 5.4.3 Padcev Sales in 2024/2023
  • 5.4.4 Adcetris Sales in 2024/2023
  • 5.4.5 Trodelvy Sales in 2024/2023
  • 5.4.6 Polivy Sales in 2024/2023
  • 5.4.7 The Next Five Years

6 ADC Recent Developments

• 6.1 Recent Developments - Importance and How to Use This Section
  • 6.1.1 Importance of These Developments
  • 6.1.2 How to Use This Section
• 6.2 Merck secures $700 million to develop ADC therapy
• 6.3 Enhertu tops Roche's Kadcyla
• 6.4 Innovent signs $11.4 billion cancer therapy deal with Takeda
• 6.5 Tubulis raises $358 million to develop targeted cancer treatments
• 6.6 Roche closes $80M deal for lung cancer ADC
• 6.7 Trodelvy and Keytruda combo succeeds in Phase 3
• 6.8 GSK acquires rights for prostate cancer ADC
• 6.9 Samsung Bioepis and Phrontline partner for ADC development
• 6.10 Phrontline Biopharma raises $60M for bispecific and dual-payload ADCs
• 6.11 Kelun has phase 3 win for ADC-Keytruda combo
• 6.12 Datopotamab deruxtecan Biologics License Application accepted
• 6.13 FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
• 6.14 AstraZeneca to build $1.5-bln ADC plant
• 6.15 Samsung Biologics expands into ADC manufacturing and services
• 6.16 Ipsen and Foreseen Biotechnology announce licensing agreement for ADC
• 6.17 PDCs vs. ADCs: A New Frontier
• 6.18 MilliporeSigma launches single-use reactor for ADC manufacturing
• 6.19 Ono to generate novel ADC candidates
• 6.20 Gilead and Tubulis to develop ADC candidate for solid tumor

7 Profiles of Key ADC Companies

• 7.1 ADC Therapeutics
• 7.2 AbbVie
• 7.3 Abzena
• 7.4 Adcendo
• 7.5 Adcentrx Therapeutics
• 7.6 Adcytherix
• 7.7 Alentis Therapeutics
• 7.8 Alphamab Oncology
• 7.9 Alteogen
• 7.10 Ambrx
• 7.11 Amgen
• 7.12 Antengene
• 7.13 Astellas Pharma
• 7.14 Axcynsis Therapeutics
• 7.15 Axplora
• 7.16 BeiGene
• 7.17 BeOne Medicines
• 7.18 BioAtla
• 7.19 Bio-Thera Solutions
• 7.20 Biotheus
• 7.21 BiVictriX Therapeutics
• 7.22 BioNTech
• 7.23 Bicycle Therapeutics
• 7.24 Bolt Biotherapeutics
• 7.25 Bright Peak Therapeutics
• 7.26 Bristol Myers Squibb (BMS)
• 7.27 Byondis
• 7.28 Callio Therapeutics
• 7.29 Catalent Biologics
• 7.30 CSPC Pharmaceutical Group
• 7.31 CytomX Therapeutics
• 7.32 Daiichi Sankyo
• 7.33 Debiopharm
• 7.34 Duality Biologics
• 7.35 Eisai
• 7.36 Eli Lilly
• 7.37 Exelixis
• 7.38 Fosun Pharma
• 7.39 Genentech (Roche)
• 7.40 Genmab
• 7.41 GenScript Biotech
• 7.42 Gilead Sciences
• 7.43 GlaxoSmithKline (GSK)
• 7.44 Hansoh Pharma
• 7.45 Hengrui Pharma
• 7.46 Heidelberg Pharma
• 7.47 Iksuda Therapeutics
• 7.48 ImmunoGen
• 7.49 Innate Pharma
• 7.50 Innovent Biologics
• 7.51 iProgen Biotech
• 7.52 Janssen Biotech (Johnson & Johnson)
• 7.53 Kelun-Biotech
• 7.54 KLUS Pharma
• 7.55 LegoChem Biosciences (LegoChemBio)
• 7.56 Lepu Biopharma
• 7.57 Lonza Pharma & Biotech / Synaffix
• 7.58 MacroGenics
• 7.59 MBrace Therapeutics
• 7.60 MediLink Therapeutics
• 7.61 Merck & Co. (MSD)
• 7.62 Merck KGaA (EMD Serono)
• 7.63 Mersana Therapeutics
• 7.64 Molecular Templates
• 7.65 NBE Therapeutics (a subsidiary of Boehringer Ingelheim)
• 7.66 Novartis
• 7.67 OBI Pharma
• 7.68 OmniAb
• 7.69 Oncomatryx
• 7.70 OnCusp Therapeutics
• 7.71 Orum Therapeutics
• 7.72 Oqory
• 7.73 Oxford BioTherapeutics
• 7.74 Pacylex Pharmaceuticals
• 7.75 Pfizer
• 7.76 Phrontline Biopharma
• 7.77 ProfoundBio
• 7.78 Promega
• 7.79 Pyxis Oncology
• 7.80 Radiance Biopharma
• 7.81 Rakuten Aspyrian (Aspyrian Therapeutics)
• 7.82 RemeGen
• 7.83 Roche
• 7.84 Rongchang Pharmaceuticals (RCBio)
• 7.85 Sanofi
• 7.86 Seagen
• 7.87 Solve Therapeutics (Solve Tx)
• 7.88 Sorrento Therapeutics
• 7.89 Starpharma
• 7.90 Sutro Biopharma
• 7.91 Synaffix (a Lonza Company)
• 7.92 SystImmune
• 7.93 Takeda Pharmaceutical
• 7.94 Tesaro / GSK Oncology
• 7.95 Tubulis
• 7.96 UCB
• 7.97 VelosBio
• 7.98 WuXi XDC
• 7.99 Xencor
• 7.100 Zai Lab

8 The Global Market for ADC Therapeutics

• 8.1 Global Market Overview by Country
  • 8.1.1 Table - Global Market by Country
  • 8.1.2 Chart - Global Market by Country
• 8.2 Global Market by Cancer - Overview
  • 8.2.1 Table - Global Market by Cancer
  • 8.2.2 Chart - Global Market by Cancer - Base/Final Year
  • 8.2.3 Chart - Global Market by Cancer - Base Year
  • 8.2.4 Chart - Global Market by Cancer - End Year
  • 8.2.5 Chart - Global Market by Cancer - Share by Year
  • 8.2.6 Chart - Global Market by Cancer - Segments Growth
• 8.3 Global Market by Payload - Overview
  • 8.3.1 Table - Global Market by Payload
  • 8.3.2 Chart - Global Market by Payload - Base/Final Year
  • 8.3.3 Chart - Global Market by Payload - Base Year
  • 8.3.4 Chart - Global Market by Payload - End Year
  • 8.3.5 Chart - Global Market by Payload - Share by Year
  • 8.3.6 Chart - Global Market by Payload - Segments Growth
• 8.4 Global Market by Target - Overview
  • 8.4.1 Table - Global Market by Target
  • 8.4.2 Chart - Global Market by Target - Base/Final Year Comparison
  • 8.4.3 Chart - Global Market by Target - Base Year
  • 8.4.4 Chart - Global Market by Target - End Year
  • 8.4.5 Chart - Global Market by Target - Share by Year
  • 8.4.6 Chart - Global Market by Target - Segments Growth
• 8.5 Global Market by Product - Overview
  • 8.5.1 Table - Global Market by Product
  • 8.5.2 Chart - Global Market by Product - Base/Final Year Comparison
  • 8.5.3 Chart - Global Market by Product - Base Year
  • 8.5.4 Chart - Global Market by Product - End Year
  • 8.5.5 Chart - Global Market by Product - Share by Year
  • 8.5.6 Chart - Global Market by Product - Segments Growth
• 8.6 Global Market by User - Overview
  • 8.6.1 Table - Global Market by User
  • 8.6.2 Chart - Global Market by User - Base/Final Year Comparison
  • 8.6.3 Chart - Global Market by User - Base Year
  • 8.6.4 Chart - Global Market by User - End Year
  • 8.6.5 Chart - Global Market by User - Share by Year
  • 8.6.6 Chart - Global Market by User - Segments Growth

9 Global ADC Markets - By Cancer

• 9.1 Breast
  • 9.1.1 Table Breast - by Country
  • 9.1.2 Chart - Breast Growth
• 9.2 Blood/Lymph Cancer
  • 9.2.1 Table Blood Cancer - by Country
  • 9.2.2 Chart - Blood Cancer Growth
• 9.3 Lung Cancer
  • 9.3.1 Table Lung Cancer - by Country
  • 9.3.2 Chart - Lung Cancer Growth
• 9.4 Other Cancer
  • 9.4.1 Table Other Cancer - by Country
  • 9.4.2 Chart - Other Cancer Growth

10 ADC Therapeutic Markets - By Payload

• 10.1 Auristatin
  • 10.1.1 Table Auristatin - by Country
  • 10.1.2 Chart - Auristatin Growth
• 10.2 Maytansinoid
  • 10.2.1 Table Maytansinoid - by Country
  • 10.2.2 Chart - Maytansinoid Growth
• 10.3 Topoisomerase
  • 10.3.1 Table Topoisomerase - by Country
  • 10.3.2 Chart - Topoisomerase Growth
• 10.4 Other Payload
  • 10.4.1 Table Other Payload - by Country
  • 10.4.2 Chart - Other Payload Growth

11 ADC Therapeutic Markets - By Target

• 11.1 HER2
  • 11.1.1 Table HER2 - by Country
  • 11.1.2 Chart - HER2 Growth
• 11.2 CD30
  • 11.2.1 Table CD30 - by Country
  • 11.2.2 Chart - CD30 Growth
• 11.3 TROP2
  • 11.3.1 Table TROP2 - by Country
  • 11.3.2 Chart - TROP2 Growth
• 11.4 CD79b
  • 11.4.1 Table CD79b - by Country
  • 11.4.2 Chart - CD79b Growth
• 11.5 Nectin 4
  • 11.5.1 Table Nectin 4 - by Country
  • 11.5.2 Chart - Nectin 4 Growth
• 11.6 Other Target
  • 11.6.1 Table Other Target - by Country
  • 11.6.2 Chart - Other Target Growth

12 ADC Therapeutic Markets - By Product

• 12.1 Enhertu
  • 12.1.1 Table Enhertu - by Country
  • 12.1.2 Chart - Enhertu Growth
• 12.2 Kadcyla
  • 12.2.1 Table Kadcyla - by Country
  • 12.2.2 Chart - Kadcyla Growth
• 12.3 Padcev
  • 12.3.1 Table Padcev - by Country
  • 12.3.2 Chart - Padcev Growth
• 12.4 Adcetris
  • 12.4.1 Table Adcetris - by Country
  • 12.4.2 Chart - Adcetris Growth
• 12.5 Trodelvy
  • 12.5.1 Table Trodelvy - by Country
  • 12.5.2 Chart - Trodelvy Growth
• 12.6 Polivy
  • 12.6.1 Table Polivy - by Country
  • 12.6.2 Chart - Polivy Growth
• 12.7 Other Product
  • 12.7.1 Table Other Product - by Country
  • 12.7.2 Chart - Other Product Growth

13 ADC Therapeutic Markets - By User

• 13.1 Clinical
  • 13.1.1 Table Clinical - by Country
  • 13.1.2 Chart - Clinical Growth
• 13.2 Trial
  • 13.2.1 Table Trial - by Country
  • 13.2.2 Chart - Trial Growth
• 13.3 Research
  • 13.3.1 Table Research - by Country
  • 13.3.2 Chart - ResearchGrowth
• 13.4 Other User
  • 13.4.1 Table Other User - by Country
  • 13.4.2 Chart - Other User Growth

14 Appendices

• 14.1 FDA Cancer Drug Approvals by Year
• 14.2 Clinical Trials Started
• 14.3 Prevalence of Cancer Treatments

Table of Tables

• Table 1 List of Cancers by Mortality
• Table 2 Overview of Innate and Adaptive Immunity
• Table 3 Some Antibody Drug Conjugate Companies
• Table 4 Market Players by Type
• Table 5 Five Factors Driving Growth
• Table 6 Four Factors Limiting Growth
• Table 7 Global Market by Region
• Table 8 Global Market by Cancer
• Table 9 Global Market by Payload
• Table 10 Global Market by Target
• Table 11 Global Market by Product
• Table 12 Global Market by User
• Table 13 Breast by Country
• Table 14 Blood Cancer by Country
• Table 15 Lung Cancer by Country
• Table 16 Other Cancer by Country
• Table 17 Auristatin by Country
• Table 18 Maytansinoid by Country
• Table 19 Topoisomerase by Country
• Table 20 Other Payload by Country
• Table 21 HER2 by Country
• Table 22 CD30 by Country
• Table 23 TROP2 by Country
• Table 24 CD79b by Country
• Table 25 Nectin 4 by Country
• Table 26 Other Target by Country
• Table 27 Enhertu by Country
• Table 28 Kadcyla by Country
• Table 29 Padcev by Country
• Table 30 Adcetris by Country
• Table 31 Trodelvy by Country
• Table 32 Polivy by Country
• Table 33 Other Product by Country
• Table 34 Clinical by Country
• Table 35 Trial by Country
• Table 36 Research by Country
• Table 37 Other User by Country

Table of Figures

• Figure 1 Medicine Expenditures Perspective
• Figure 2 Helper T Cell Roles
• Figure 3 Antibody Diagram
• Figure 4 Macrophages attack a Cancer Cell
• Figure 5 Antibody Drug Conjugate Diagram
• Figure 6 Growth rates of ADC Therapies
• Figure 7 Global Market Pareto Chart
• Figure 8 Global Market by Cancer - Base vs. Final
• Figure 9 Global Market by Cancer Base Year
• Figure 10 Global Market by Cancer End Year
• Figure 11 Cancer Share by Year
• Figure 12 Cancer Segments Growth
• Figure 13 Global Market by Payload - Base vs. Final
• Figure 14 Global Market by Payload Base Year
• Figure 15 Global Market by Payload End Year
• Figure 16 Payload Share by Year
• Figure 17 Payload Segments Growth
• Figure 18 Global Market by Target - Base vs. Final
• Figure 19 Global Market by Target Base Year
• Figure 20 Global Market by Target End Year
• Figure 21 Target Share by Year
• Figure 22 Target Segments Growth
• Figure 23 Global Market by Product - Base vs. Final
• Figure 24 Global Market by Product Base Year
• Figure 25 Global Market by Product End Year
• Figure 26 Product Share by Year
• Figure 27 Product Segments Growth
• Figure 28 Global Market by User - Base vs. Final
• Figure 29 Global Market by User Base Year
• Figure 30 Global Market by User End Year
• Figure 31 User Share by Year
• Figure 32 User Segments Growth
• Figure 33 Breast Growth
• Figure 34 Blood Cancer Growth
• Figure 35 Lung Cancer Growth
• Figure 36 Other Cancer Growth
• Figure 37 Auristatin Growth
• Figure 38 Maytansinoid Growth
• Figure 39 Topoisomerase Growth
• Figure 40 Other Payload Growth
• Figure 41 HER2 Growth
• Figure 42 CD30 Growth
• Figure 43 TROP2 Growth
• Figure 44 CD79b Growth
• Figure 45 Nectin 4 Growth
• Figure 46 Other Target Growth
• Figure 47 Enhertu Growth
• Figure 48 Kadcyla Growth
• Figure 49 Padcev Growth
• Figure 50 Adcetris Growth
• Figure 51 Trodelvy Growth
• Figure 52 Polivy Growth
• Figure 53 Other Product Growth
• Figure 54 Clinical Growth
• Figure 55 Trial Growth
• Figure 56 Research Growth
• Figure 57 Other User Growth
• Figure 58 FDA Cancer Drug Approvals by Year
• Figure 59 Clinical Trials for Immunotherapy by Year
• Figure 60 Pie Chart of Prevalence of Cancer Treatments